CADD522

News alerts, weekly reports and conference planners

Company:

University of East Anglia, University of Maryland Medical System

Drug class:

RUNX2 inhibitor

‹

›

7ms

RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma. (PubMed, bioRxiv)

RUNX2 inhibition reduces PAX3::FOXO1 expression and signaling, which impairs fusion-positive rhabdomyosarcoma oncogenic phenotypes. In vivo treatment with CADD522 decreased tumor growth and increased survival, indicating that RUNX2 is a promising therapeutic target.

7 months ago

Journal

FOXO1 (Forkhead box O1) • MYOD1 (Myogenic Differentiation 1) • PAX3 (Paired Box 3) • RUNX2 (RUNX Family Transcription Factor 2) • YOD1 (YOD1 Deubiquitinase)

CADD522

almost3years

YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522. (PubMed, J Bone Oncol)

In xenograft mouse models, CADD522 as a single agent without surgery significantly reduced tumour volume, increased overall and metastasis-free survival and reduced cancer-induced bone disease. Our results provide insight into PBC molecular abnormalities that have led to the identification of new targets and a new therapeutic.

almost 3 years ago

Journal

YBX1 (Y-Box Binding Protein 1) • MIR140 (MicroRNA 140) • RUNX2 (RUNX Family Transcription Factor 2)

CADD522